Literature DB >> 1446848

New forms of treatment for inflammatory bowel disease.

D Rachmilewitz1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1446848      PMCID： PMC1379592          DOI： 10.1136/gut.33.10.1301

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  9 in total

1.  A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn's disease.

Authors:  J Brynskov; L Freund; S N Rasmussen; K Lauritsen; O S de Muckadell; N Williams; A S MacDonald; R Tanton; F Molina; M C Campanini
Journal:  N Engl J Med       Date:  1989-09-28       Impact factor: 91.245

2.  Role of platelet-activating factor in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine and prednisolone.

Authors:  R Eliakim; F Karmeli; E Razin; D Rachmilewitz
Journal:  Gastroenterology       Date:  1988-11       Impact factor: 22.682

3.  Fluticasone propionate in Crohn's disease.

Authors:  M C de Kaski; A M Peters; J P Lavender; H J Hodgson
Journal:  Gut       Date:  1991-06       Impact factor: 23.059

4.  A controlled randomized trial of budesonide versus prednisolone retention enemas in active distal ulcerative colitis.

Authors:  A Danielsson; G Hellers; E Lyrenäs; R Löfberg; A Nilsson; O Olsson; S A Olsson; T Persson; L Salde; J Naesdal
Journal:  Scand J Gastroenterol       Date:  1987-10       Impact factor: 2.423

5.  4-Aminosalicylic acid, in contrast to 5-aminosalicylic acid, has no effect on arachidonic acid metabolism in human neutrophils, or on the free radical 1,1-diphenyl-2-picrylhydrazyl.

Authors:  O H Nielsen; I Ahnfelt-Rønne
Journal:  Pharmacol Toxicol       Date:  1988-04

6.  Treatment of left-sided ulcerative colitis with 4-aminosalicylic acid enemas. A double-blind, placebo-controlled trial.

Authors:  A L Ginsberg; L S Beck; T M McIntosh; L E Nochomovitz
Journal:  Ann Intern Med       Date:  1988-02       Impact factor: 25.391

7.  Release of platelet-activating factor (PAF) and accelerated healing induced by a PAF antagonist in an animal model of chronic colitis.

Authors:  J L Wallace
Journal:  Can J Physiol Pharmacol       Date:  1988-04       Impact factor: 2.273

8.  Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease.

Authors:  R A Kozarek; D J Patterson; M D Gelfand; V A Botoman; T J Ball; K R Wilske
Journal:  Ann Intern Med       Date:  1989-03-01       Impact factor: 25.391

9.  Preliminary report: cyclosporin in treatment of severe active ulcerative colitis.

Authors:  S Lichtiger; D H Present
Journal:  Lancet       Date:  1990-07-07       Impact factor: 79.321
  9 in total
  2 in total

1.  A modest proposal for future trials of medical treatment in inflammatory bowel disease.

Authors:  H D Janowitz
Journal:  Gut       Date:  1994-06       Impact factor: 23.059

Review 2.  Future therapeutic approaches for inflammatory bowel diseases.

Authors:  Scott E Plevy; Stephan R Targan
Journal:  Gastroenterology       Date:  2011-05       Impact factor: 22.682
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.